Corporate - Media & Press
Arrayit Extends Worldwide Licensing of Its Patented High-Throughput Genotyping Platform
FOR IMMEDIATE RELEASE: January 15, 2009
Integrated Media Holdings, Inc. (OTCBB: IMHI) announced today that its wholly owned subsidiary, Arrayit Corporation doing business as Arrayit Company, has entered into a licensing agreement with The Research Institute for Epidemiology and Microbiology (RIEM) for the supply and license rights of the state-of-the-art patented microarray platform and associated reagents. The Arrayit platform will empower RIEM to deploy Arrayit's massively parallel high-throughput genotyping platform to screen and test a large number of patient samples quickly, affordably and accurately.
Ms. Rene Schena, CEO of Arrayit, stated, "Arrayit is pleased to license our patented genotyping platform to RIEM. We believe that the capacity to easily and affordably screen a large number of patient samples for disease-carrying traits will be transformative in health care."
Pursuant to a contract signed between the parties on June 30th, 2008, and effective with its funding on January 9, 2009, this licensing agreement permits RIEM to utilize the Arrayit's sophisticated multi-patient genotyping platform to examine the DNA of many patient samples at once. The agreement also gives RIEM the right to use Arrayit's patented contact printing technology for diagnostic applications.
About Arrayit Company
Integrated Media Holdings, Inc. owns, as a wholly owned subsidiary, TeleChem International, Inc., which is doing business as Arrayit Company, and is headquartered in Sunnyvale, California. Arrayit leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. It now offers over 150 products to a customer base of more than 2,500 laboratories worldwide, including most every major university, pharmaceutical and biotech company, major agricultural and chemical company, government agency, national research foundation and many private sector enterprises. Please visit www.arrayit.com for more information.
The Research Institute for Epidemiology and Microbiology (RIEM) is a present-day and advanced National R&D Center, where a wide range of fundamental studies in the area of epidemiology, medical virology, microbiology, immunology and parasitology are conducted. Additionally, the Institute performs a huge scope of applied investigations (virological, bacteriologic and immunologic) by the orders of the Belarusian Ministry of Public Health, the State Committee on Science and Technologies, medical care services and other institutions. Experts from the Institute accomplish methodical supervision, issue guidelines and instructions on bulk of problems related to communicable diseases. The researchers develop and manufacture by original technologies medicines, diagnostic and prophylactic preparations, render consultations on methods of investigations and diagnosis of infections, on the approaches to their treatment and prevention.
Safe Harbor Statement
Except for historical information contained herein, statements made in this release that would constitute forward-looking statements may involve certain risks and uncertainties. All forward-looking statements made in this release are based on currently available information and the Company assumes no responsibility to update any such forward-looking statement. The following factors, among others, may cause actual results to differ materially from the results suggested in the forward-looking statements. The factors include, but are not limited to, risks that may result from changes in the Company's business operations; our ability to keep pace with technological advances; significant competition in the biomedical business; our relationships with key suppliers and customers; quality and consumer acceptance of newly introduced products; market volatility; non-availability of product; excess inventory; price and product competition; new product introductions, the outcome of our legal disputes; the possibility that the review of our prior filings by the SEC may result in changes to our financial statements; and the possibility that stockholders or regulatory authorities may initiate proceedings against Arrayit and/or our officers and directors as a result of any restatements. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2007 and Form 10-Q/A for the fiscal first quarter ended March 31, 2008 and Form 10-Q for the fiscal second quarter ended June 30, 2008.
Copyright 1993-2018 Arrayit Corporation. All rights reserved.